K2 Therapeutics raises $50M seed, taps ex-Legend Biotech chief as CEO

What's the deal? Singapore-based biotech K2 TherapeuticsDealroom has a profile for this one. Try Dealroom → has secured a $50 million seed round led by MPM BioImpactDealroom has a profile for this one. Try Dealroom →, the investment firm that founded the company. K2 aims to identify promising drug candidates from around the world and translate them into medicines.

Why now? The company simultaneously appointed Huang Ying, former chief executive of Nasdaq-listed Legend Biotech, as its new CEO. His immediate focus is raising a Series A to develop K2's four existing assets, with interest already coming from healthcare funds.

The hire: At Legend Biotech, Huang led the development and commercialisation of cell therapies, growing the company from a Phase 1 clinical-stage firm to a fully integrated biopharmaceutical business with more than 3,000 staff across the US, Europe, and China. He was previously head of biotech research at Merrill LynchDealroom has a profile for this one. Try Dealroom →.

What's the endgame? K2 will expand its business development, clinical, and manufacturing teams in Asia and the US, while continuing to search for assets to acquire and develop. It runs a hub-and-spoke model, centralising leadership and strategy while advancing assets in parallel.

"K2 was founded to help unlock that potential, combining a global search for exceptional science with deep drug development expertise and the resources needed to translate innovation into impact for patients worldwide," said Ansbert Gadicke, chairman of K2 and managing partner of MPM BioImpact.

The signal: At $50 million, K2's seed sits in the top 1% of all health-sector seed rounds recorded in the US. The scale reflects growing investor conviction in Asia-Pacific drug innovation — Huang points to novel mechanisms and capital-efficient proof-of-concept data emerging from the region.

Read more: Business Times

Image credit: Generated with Gemini